Toggle light / dark theme

High-energy, short-pulse laser sources exist only in a limited number of colors. Researchers in the 1960s found that a liquid-filled cell, which had inadvertently been placed inside a laser’s cavity, shifted the laser’s wavelength. Now a team of scientists from Brookhaven National Laboratory (BNL), New York, show that synthetic, room-temperature liquid salts can also serve as effective laser-color-tuning media [1]. The finding could lead to a simple and energy-efficient tool for creating lasers with desired colors for medical and scientific applications.

In the 1960’s liquid technique, when a photon “hits” a liquid molecule, the photon loses energy, exiting the medium with less energy—and thus a different color—than it entered (see Focus: Holey Fibers Shed New Light). The BNL team reasoned that a salt solution could interact with photons in the same way while offering a high density of energy-swapping sites compared to either a gas or a standard liquid. The vast array of available artificial salts could also make it possible to precisely tune the energy loss caused by the salt–photon interaction, giving increased color control.

The researchers assembled their converter setup from a pulsed green laser and a 63-cm-long cell filled with a salt solution. Passing the laser through the cell, they observed that the light turned orange. The researchers measured a high color-conversion efficiency of the photons, which they attribute to the large interaction cross sections of the salt molecules and to the reduction of other forms of scattering that can inhibit wavelength conversion. The group is currently designing liquids to turn this and other lasers to myriad colors.

Gene therapies have the potential to treat neurological disorders like Alzheimer’s and Parkinson’s diseases, but they face a common barrier—the blood-brain barrier. Now, researchers at the University of Wisconsin-Madison have developed a way to move therapies across the brain’s protective membrane to deliver brain-wide therapy with a range of biological medications and treatments.

“There is no cure yet for many devastating disorders,” says Shaoqin “Sarah” Gong, UW-Madison professor of ophthalmology and visual sciences and biomedical engineering and researcher at the Wisconsin Institute for Discovery. “Innovative brain-targeted delivery strategies may change that by enabling noninvasive, safe and efficient delivery of CRISPR genome editors that could, in turn, lead to genome-editing therapies for these diseases.”

CRISPR is a molecular toolkit for editing (for example, to correct mutations that may cause disease), but the toolkit is only useful if it can get through security to the job site. The is a membrane that selectively controls access to the brain, screening out toxins and pathogens that may be present in the bloodstream. Unfortunately, the bars some beneficial treatments, like certain vaccines and gene therapy packages, from reaching their targets because in lumps them in with hostile invaders.

A study conducted in Brazil and reported in an article published in Molecular Psychiatry suggests that schizophrenia may be associated with alterations in the vascularization of certain brain regions. Researchers at the State University of Campinas (UNICAMP), D’Or Research and Education Institute (IDOR) and the Federal University of Rio de Janeiro (UFRJ) found a link between astrocytes (central nervous system cells) from patients with schizophrenia and formation of narrow blood vessels.

Schizophrenia is a severe multifactorial mental health disorder affecting around 1% of the world population. Common symptoms include loss of contact with reality (psychosis), hallucinations (hearing voices, for example), delusions or delirium, disorganized motor behavior, loss of motivation and cognitive impairment.

In the study, the researchers focused on the role of astrocytes in development of the disease. These glial cells are housekeepers of the central nervous system and important to its defense. They are the central elements of the neurovascular units that integrate neural circuitry with local blood flow and provide neurons with metabolic support.

Michael Levin is an American developmental and synthetic biologist at Tufts University. His research interests include: bioelectrical signals by which cells communicate to serve the dynamic anatomical needs of the organism during development, regeneration, and cancer suppression; basal cognition and intelligence in diverse unconventional substrates; and top-down control of form and function across scales in biology.

Join us as we discuss.
- Bioelectricity.
- Regeneration.
- The future in medicine.
- The act of free will and more.

EPISODE LINKS:
Michael’s Twitter: https://twitter.com/drmichaellevin.
Michael’s Website: https://drmichaellevin.org.
Michael’s Publications: https://facultyprofiles.tufts.edu/michael-levin-1/publications.

PODCAST INFO:
Podcast website: https://www.rekindi.com/podcasts.
Apple Podcasts: https://podcasts.apple.com/gb/podcast/rekindi-podcast/id1550253946
Spotify: https://open.spotify.com/show/1Gn2DZjxvLnZ88bh2fgLWn?si=c714c46c9d09449a

Summary: A newly developed machine learning model can predict the words a person is about to speak based on their neural activity recorded by a minimally invasive neuroprosthetic device.

Source: HSE

Researchers from HSE University and the Moscow State University of Medicine and Dentistry have developed a machine learning model that can predict the word about to be uttered by a subject based on their neural activity recorded with a small set of minimally invasive electrodes.

There are around 42,900 new bowel cancer cases in the UK every year Experts have hailed “remarkable” new research which shows that giving chemotherapy before surgery for early-stage bowel cancer cuts the chance of the disease coming back by 28%. The study, funded by Cancer Research UK, suggests at least 5,000 patients in the UK every year could benefit from a tweak to how they receive chemotherapy.

Researchers from the Andrew and Erna Viterbi Faculty of Electrical and Computer Engineering at the Technion—Israel Institute of Technology have presented the first experimental observation of Cherenkov radiation confined in two dimensions. The results represent a new record in electron-radiation coupling strength, revealing the quantum properties of the radiation.

Cherenkov is a unique physical phenomenon, which for many years has been used in medical imaging and in particle detection applications, as well as in laser-driven electron accelerators. The breakthrough achieved by the Technion researchers links this phenomenon to future photonic quantum computing applications and free-electron quantum light sources.

The study, which was published in Physical Review X, was headed by Ph.D. students Yuval Adiv and Shai Tsesses from the Technion, together with Hao Hu from the Nanyang Technological University in Singapore (today professor at Nanjing university in China). It was supervised by Prof. Ido Kaminer and Prof. Guy Bartal of the Technion, in collaboration with colleagues from China: Prof. Hongsheng Chen, and Prof. Xiao Lin from Zhejiang University.

Talk Title: Human Age Reversal through Mitochondrial Transplantation.

Tom Benson, CEO at Mitrix Bio, presents at Investing in the Age of Longevity 2022. In his talk, Tom outlines the effect of mitochondria on aging, and how mitochondrial transplantation can be used for age reversal. Showcasing how Mitrix Bio is pioneering the application of this technique, Tom also presents the company’s roadmap for clinical trials and commercialisation of its platform.

Download the presentation slides: https://bit.ly/IAL22-Tom-Benson.

Investing in the Age of Longevity 2022 was held in London on 17 November 2022. The one-day masterclass featured presentations from scientists and business leaders at the cutting edge of the field, giving participants the inside track on the latest aging-related discoveries and investment opportunities.

Download the event programme: https://www.masterinvestor.co.uk/IAL22

Find out more about past and upcoming Master Investor events: https://events.masterinvestor.co.uk